Trials / NCT07602803
The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK
Completed Observational Natural history / observational
- Sponsor
- The Queen Elizabeth Hospital
- Treatment
- Not listed
- Gene
- Not stated
- Conditions
- Bardet-Biedl Syndrome
- Ages
- 18 Years to no upper limit
- Enrollment
- 300 participants
- Started
- 2023-01-01
- Main results expected
- 2026-04-01
- Results posted
- Not yet
- Record last updated
- 2026-05-27
What the study is testing
The goal of this observational study is to learn about the long-term effects of GLP1 agonists (weight loss jab, including Mounjaro) in patients with Bardet-Biedl Syndrome (BBS) who take GLP1 agonists to treat high body weight. The main question:
Do GLP1 agonists effectively and safely lower body weight in patients with BBS when taken long-term, compared to patients not on these medications? The investigators look at the change (%) in weight during the observational periods.
Where it runs
United Kingdom (1)
- Queen Elizabeth Hospital Birmingham, Birmingham, West Midlands